A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma

This is a first-in-human study testing a new type of engineered T-cell therapy called ATTiL12 — immune cells anchored with a molecule that activates and guides them to attack tumors — in people with advanced or metastatic soft tissue or bone sarcoma. **You may be eligible if...** - You are 12 years old or older with confirmed advanced or metastatic soft tissue or bone sarcoma (including osteosarcoma) - You have received at least one prior standard therapy, unless no standard treatment exists for your sarcoma subtype - Your general health score is 0 or 1 - At least 3 weeks have passed since your last chemotherapy or immunotherapy - Your cancer is measurable on imaging **You may NOT be eligible if...** - You have not had enough time since your last cancer treatment - You have received another investigational drug recently - Your organ function does not meet required minimums - You have uncontrolled serious health conditions Talk to your doctor to see if this trial is right for you.